Comparative Pharmacology
Head-to-head clinical analysis: OVRAL versus PROCOMP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVRAL versus PROCOMP.
OVRAL vs PROCOMP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.
One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.
50 mg orally once daily
None Documented
None Documented
Norgestrel: 24–32 hours; Ethinyl estradiol: 12–18 hours; steady-state achieved after 5–7 days
Terminal elimination half-life: 12-18 hours (mean 15 hours). Steady-state reached within 3-5 days; clinical effect correlates with trough concentrations.
Renal (60% as metabolites, ~40% unchanged); biliary/fecal (40%)
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; total recovery ~90% in urine and feces within 72 hours.
Category C
Category C
Oral Contraceptive
Oral Contraceptive